EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)

Takahiro Nakayama, Naoki Niikura, Takashi Yamanaka, Mitsugu Yamamoto, Kazuo Matsuura, Kenichi Inoue, Sachiko Takahara, Hironori Nomura, Shosuke Kita, Miki Yamaguchi, Tomoyuki Aruga, Nobuhiro Shibata und 8 weitere

Breast Cancer · 2024

DOI: 10.1007/s12282-024-01614-1 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Breast Cancer, 2024. Verfasst von Takahiro Nakayama und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Endocrine Surgery, Osaka International Cancer Institute, Osaka, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Trastuzumab, Erb-b2 Receptor Tyrosine Kinases, Brain Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Daiichi-Sankyo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We provide updated results (median follow-up duration: 20.4 months) of a retrospective study on the effectiveness of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer with brain metastases (BM) and/or leptomeningeal disease (ROSET-BM). Median progression-free survival (PFS) was 14.6 months. Median overall survival (OS) was not reached (NR); 24-month OS rate was 56.0%. Subgroup analysis showed that median PFS was 13.2 months in patients with analytical active BM, 17.5 months in patients with leptomeningeal carcinomatosis (LMC), and NR in patients with analytical stable BM (24-month PFS rates in patients with analytical active BM, LMC, and analytical stable BM were 32.7%, 25.1%, and 60.8%, respectively). Median OS was 27.0 months in patients with analytical active BM and NR in patients with LMC or analytical stable BM (24-month OS rates in patients with analytical active BM, LMC, and analytical stable BM were 52.0%, 61.6%, and 71.6%, respectively). The most common adverse event leading to discontinuation of T-DXd was interstitial lung disease (ILD; 23.1%); median ILD onset time among patients who discontinued T-DXd treatment due to ILD was 5.3 months. T-DXd has promising effectiveness in heavily pre-treated HER2+ metastatic breast cancer patients with BM and LMC. The incidence and median onset time of ILD were similar to those of Japanese subgroups in previous studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTrastuzumabErb-b2 Receptor Tyrosine KinasesBrain NeoplasmsCamptothecinHumansFemaleRetrospective StudiesMiddle AgedAdultAgedMeningeal NeoplasmsMeningeal CarcinomatosisImmunoconjugatesAntineoplastic Agents, ImmunologicalProgression-Free Survival

Stichwörter der Autor:innen

Brain metastasisBreast cancerHER2+LeptomeningealTrastuzumab deruxtecan

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesCamptothecinImmunoconjugatesAntineoplastic Agents, Immunologicaltrastuzumab deruxtecanERBB2 protein, human

Autor:innen und Institutionen

  • Department of Breast and Endocrine Surgery, Osaka International Cancer Institute, Osaka, Japan.
  • Department of Breast Oncology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan. nniikura@tokai.ac.jp.
  • Department of Breast Surgery and Oncology, Kanagawa Cancer Center, Kanagawa, Japan.
  • Department of Breast Oncology, Hokkaido Cancer Center, Hokkaido, Japan.
  • Department of Breast Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
  • Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan.

Förderung

  • Daiichi-Sankyo

Zitieren

APA

Nakayama, T., Niikura, N., Yamanaka, T., Yamamoto, M., Matsuura, K., Inoue, K., Takahara, S., Nomura, H., Kita, S., Yamaguchi, M., Aruga, T., Shibata, N., Shimomura, A., Ozaki, Y., Sakai, S., Takiguchi, D., Takata, T., Bastanfard, A., Shiosakai, K., & Tsurutani, J. (2024). Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM). Breast Cancer. https://doi.org/10.1007/s12282-024-01614-1

Vancouver

Nakayama T, Niikura N, Yamanaka T, Yamamoto M, Matsuura K, Inoue K, et al. Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM). Breast Cancer. 2024. doi:10.1007/s12282-024-01614-1

BibTeX
@article{Nakayama2024,
  author = {Nakayama, Takahiro and Niikura, Naoki and Yamanaka, Takashi and Yamamoto, Mitsugu and Matsuura, Kazuo and Inoue, Kenichi and Takahara, Sachiko and Nomura, Hironori and Kita, Shosuke and Yamaguchi, Miki and Aruga, Tomoyuki and Shibata, Nobuhiro and Shimomura, Akihiko and Ozaki, Yuri and Sakai, Shuji and Takiguchi, Daisuke and Takata, Takehiko and Bastanfard, Armin and Shiosakai, Kazuhito and Tsurutani, Junji},
  title = {Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)},
  journal = {Breast Cancer},
  year = {2024},
  doi = {10.1007/s12282-024-01614-1}
}
Kostenlos starten →